Department of Biopharmaceutics and Drug Metabolism, Graduate School of Pharmaceutical Science, Kyoto University, Sakyo-Ku, Kyoto 606-8501, Japan.
J Pharm Sci. 2010 Apr;99(4):2176-84. doi: 10.1002/jps.21975.
Empirically, 3-6 samples at each sampling time point have been used for most preclinical one-point sampling experiments without any theoretical justification. The purpose of the present study is to propose a practical approach to determine the minimum sample number (N(min)) based on Monte Carlo simulation and a bootstrap resampling. A computer program MOMENT(BS), in which a bootstrap resampling algorithm is used to estimate mean and standard deviations of pharmacokinetic parameters, such as area under the curve and mean residence time, was applied to estimate N(min). A new simulation program, MONTE1, was developed to generate simulated data for bootstrap resampling using the model parameters including inter- and/or intra-individual variations. Then, an index, S(2)CV calculated as the sum of the squared coefficient of variation is proposed to determine the N(min). The proposed approach was applied to the actual data in preclinical experiments, and the usefulness of the approach was suggested. An issue that one-point sampling data cannot separately assess inter- and intra-individual variability is discussed.
从经验上看,大多数临床前单点采样实验在每个采样时间点使用了 3-6 个样本,但没有任何理论依据。本研究的目的是提出一种实用的方法,基于蒙特卡罗模拟和自举重采样来确定最小样本量 (N(min))。计算机程序 MOMENT(BS) 应用自举重采样算法来估计药代动力学参数(如曲线下面积和平均驻留时间)的均值和标准差,用于估计 N(min)。开发了一个新的模拟程序 MONTE1,用于使用包括个体内和/或个体间变异的模型参数生成用于自举重采样的模拟数据。然后,提出了一个指数 S(2)CV,它被计算为变异系数的平方和,用于确定 N(min)。该方法应用于临床前实验中的实际数据,并提出了该方法的有用性。讨论了单点采样数据无法分别评估个体内和个体间变异性的问题。